Large long-term studies of sirolimus-eluting and paclitaxel-eluting stents are inconclusive
This article has no abstract so we have provided the first paragraph of the full text.
Two recent papers have investigated the safety of drug-eluting stents (DESs), and have also compared the two FDA-approved DESs—sirolimus-eluting stents (SESs) and paclitaxel-eluting stents (PESs).
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
